Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

United States.

Net loss for the first quarter of 2009 was approximately $4.6 million, compared to a net loss of approximately $8.0 million for the first quarter of 2008. Net loss per share attributable to common stockholders was $0.26 per share and $0.46 per share for the three months ended March 31, 2009 and 2008, respectively, based on weighted average shares outstanding of 17,568,600 and 17,468,395 respectively.

Cash, cash equivalents and short-term investments were approximately $18.8 million at March 31, 2009, compared to $24.5 million at December 31, 2008.

Stephen Ghiglieri, CFO, commented, "We have focused our cash resources to prosecute our MAA and NDA for Qutenza and to support strategies for obtaining adequate reimbursement for Qutenza in the United States, while deferring further clinical development of Qutenza, NGX-1998 and our preclinical prodrug development programs. As a result of our conservative cost management strategy, we believe that our cash runway is sufficient to last at least until December 31, 2009. Potential near-term proceeds from a European commercial partnership, which we expect to finalize in the first half of 2009, would provide additional runway and have not been accounted for in our current cash forecast. As we pursue European and U.S. commercial partnerships, and other non-equity based sources of funding, we do not currently intend to raise equity capital in the public markets at our present valuation."

Development Update

Currently, NeurogesX is primarily focused on completing the development through regulatory approval, of Qutenza for patients with PHN in the United States and for peripheral neuropathic pain in non-diabetic adults in the E.U.

The CHMP's positive opinion recommending E.U. approval of Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination wi
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... --  BioTE Medical , a leading provider of ... today announced the addition of Dr. Neal ... is joining the BioTE Medical Advisory Board as ... was residency trained in Family Medicine and Emergency ... emergency physician still practicing at a large metropolitan ...
(Date:7/22/2014)... The DNA Spectrum Ancestry Map provides ... history, migration, and culture. , Throughout his childhood ... stories stemming from Europe. His father passionately referred to ... 8mm home movies painted an elaborate picture of an ... ordered a test from DNA Spectrum to expand upon ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
(Date:7/22/2014)... 22, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today announced that it will report second ... U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., ... conference call at 11 a.m. EDT, July 25, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... BEDMINSTER, N.J., Nov. 8, 2010 Omthera ... company, today announced the initiation of a ... evaluate the bioavailability of Epanova™, Omthera,s lead ... triglycerides, in comparison to Lovaza®, the leading ...
... (Nasdaq: TPCG ) today announced that it has commenced ... of its common stock at a purchase price of not less ... purchase shares having an aggregate purchase price of no more than ... stockholders may tender all or a portion of their shares (1) ...
... at the Kavli Institute of NanoScience, has been awarded ... his research into improved microscopic technologies. The technologies enable ... semiconductor nanowires, all the way down to atomic level. ... are made visible in this way can be measured ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 2TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 3TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock 4ERC advanced grant for Professor Zandbergen's 'nanolaboratory' 2
(Date:7/22/2014)... Arlington computer science and engineering professor with an expertise ... National Science Foundation grant worth more than $600,000 to ... fruit fly., Heng Huang, an associate professor, will lead ... UT Arlington Computer Science and Engineering department. Scientists are ... a large number of genes involved in fruit fly ...
(Date:7/22/2014)... the average steak, but it seems to help wood ... winter cold. , "Alaska wood frogs spend more time ... your freezer and the frog comes back to life ... said Don Larson, University of Alaska Fairbanks graduate student ... freeze tolerance in Alaska wood frogs is more extreme ...
(Date:7/22/2014)... the USC Schaeffer Center for Health Policy and ... drugs with increased incarceration rates for schizophrenic individuals. ... whether cutbacks in mental health actually save money, ... Some health plans require an extra approval step ... patients. This step called prior authorization ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... Sept. 26 2007 -- Consuming large amounts of caffeine ... painkillers in the United States, could potentially cause liver ... the Oct. 15 print issue of ACS Chemical Research ... occur not only from drinking caffeinated beverages while taking ...
... the magnetic reference direction, have recently been found in ... 2004). Furthermore, studies investigating what parts of a migratory ... magnetic compass showed that the cryptochrome-containing neurons in the ... al., PNAS, 2005; Liedvogel et al., EJN, 2007) are ...
... 25, 2007) Your body goes to a lot of ... brains neural pathways are impaired through injury, age or illness, ... to perform the constant yet delicate balancing act required for ... robots that can balance like humans, researchers at Georgia Tech ...
Cached Biology News:Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 2Simulation reveals how body repairs balance after damage 2Simulation reveals how body repairs balance after damage 3